MX2017002364A - Terapia de combinacion para tratamiento de cancer. - Google Patents

Terapia de combinacion para tratamiento de cancer.

Info

Publication number
MX2017002364A
MX2017002364A MX2017002364A MX2017002364A MX2017002364A MX 2017002364 A MX2017002364 A MX 2017002364A MX 2017002364 A MX2017002364 A MX 2017002364A MX 2017002364 A MX2017002364 A MX 2017002364A MX 2017002364 A MX2017002364 A MX 2017002364A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
combination therapy
combination
staggered
Prior art date
Application number
MX2017002364A
Other languages
English (en)
Inventor
Gurney Austin
Ching YEN Wan-
Original Assignee
Oncomed Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc filed Critical Oncomed Pharm Inc
Publication of MX2017002364A publication Critical patent/MX2017002364A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

La presente invención provee métodos que comprenden terapia de combinación para el tratamiento de cáncer. Inhibidores de la vía Wnt en combinación con inhibidores de mitosis son administrados en forma de dosificación escalonada o secuencial para el tratamiento de cáncer y otras enfermedades.
MX2017002364A 2014-08-27 2015-08-27 Terapia de combinacion para tratamiento de cancer. MX2017002364A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462042710P 2014-08-27 2014-08-27
US201462086376P 2014-12-02 2014-12-02
US201562134661P 2015-03-18 2015-03-18
PCT/US2015/047102 WO2016033284A1 (en) 2014-08-27 2015-08-27 Combination therapy for treatment of cancer

Publications (1)

Publication Number Publication Date
MX2017002364A true MX2017002364A (es) 2017-05-17

Family

ID=55400550

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002364A MX2017002364A (es) 2014-08-27 2015-08-27 Terapia de combinacion para tratamiento de cancer.

Country Status (9)

Country Link
US (1) US20170247465A1 (es)
EP (1) EP3185884A4 (es)
JP (1) JP2017526676A (es)
CN (1) CN106714822A (es)
AU (1) AU2015308854A1 (es)
CA (1) CA2959529A1 (es)
MA (1) MA40364A (es)
MX (1) MX2017002364A (es)
WO (1) WO2016033284A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
EP4183806A3 (en) 2014-11-12 2023-08-02 Seagen Inc. Glycan-interacting compounds and methods of use
US20180244783A1 (en) * 2015-08-31 2018-08-30 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
IL302822A (en) 2015-11-12 2023-07-01 Seagen Inc Compounds interacting with glycans and methods of use
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
KR102653141B1 (ko) 2017-03-03 2024-04-01 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
WO2019124603A1 (ko) * 2017-12-22 2019-06-27 경상대학교병원 Iwr-1을 유효성분으로 함유하는 켈로이드 예방 또는 치료용 조성물
JP7369968B2 (ja) * 2017-12-27 2023-10-27 公益財団法人がん研究会 抗がん剤
EP3784240B1 (en) * 2018-04-24 2023-09-20 Universidade do Minho Wnt6 as glioblastoma oncogenic biomarker, and uses of inhibitors thereof for treating wnt6-overexpressing glioblastoma
CN113648425B (zh) * 2021-08-18 2022-05-03 中国人民解放军军事科学院军事医学研究院 Plk1抑制剂和csnk1d/e抑制剂对肿瘤细胞具有协同抑制作用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551789B2 (en) * 2010-04-01 2013-10-08 OncoMed Pharmaceuticals Frizzled-binding agents and their use in screening for WNT inhibitors
SG190568A1 (en) * 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
EP2911691B1 (en) * 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
JP2016510411A (ja) * 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング

Also Published As

Publication number Publication date
EP3185884A4 (en) 2018-04-11
JP2017526676A (ja) 2017-09-14
MA40364A (fr) 2016-03-03
WO2016033284A1 (en) 2016-03-03
AU2015308854A1 (en) 2017-03-02
EP3185884A1 (en) 2017-07-05
CA2959529A1 (en) 2016-03-03
CN106714822A (zh) 2017-05-24
US20170247465A1 (en) 2017-08-31
WO2016033284A4 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
IL272948A (en) ENPP1 inhibitors and their use for cancer treatment
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
HRP20190117T1 (hr) iRNK TERAPIJA ZA LIJEČENJE BOLESTI OKA
PH12017500601A1 (en) Anti-tnf compounds
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
HK1252813A1 (zh) 用於治療社交障礙和藥物使用障礙的治療性化合物和組合物
PL3242947T3 (pl) Terapia genowa i elektroporacja do leczenia zmian złośliwych
IL247586A0 (en) Use of Aribolin and mtor inhibitors as a combined treatment for cancer
MX2017011018A (es) Inhibicion de la actividad de olig2.
EP3156054A4 (en) Medicine for preventing and/or treating stress-induced diseases
IL248328A0 (en) Bracelets for the administration of drugs for the treatment of resistant cancer and for the use of combined therapy
HK1258235A1 (zh) 在癌症治療中用於傳播病毒的PI3K P-δ110亞型抑制劑
IL245861A0 (en) Use of substances to treat drug-resistant tumors
PH12020500472A1 (en) Autotaxin inhibitor compounds
GB201416605D0 (en) Combination therapy to reduce the risk of and to treat cancer